Oct 30 2010
Roche has declared that it received FDA approval for its PCR COBAS TaqMan HCV Test, v2.0, which can determine the quantity of hepatitis C viral RNA present in the HCV affected humans’ serum or plasma sample.
It includes COBAS TaqMan 48 Analyzer for automated identification and amplification of specimen prepared by both automated and manual methods. Innovative contamination controls are incorporated into COBAS TaqMan assays. All these features facilitate clinicians to monitor the hepatitis C patients more effectively and to enhance the outcomes of the treatment.
Teresa Wright, Chief Medical Officer of Roche Molecular Diagnostics, has stated that this innovative HCV testing system can determine the competencies of many anti-hepatitis C samples, which are presently in the development phase. She added that Roche is dedicated to offering entire investigation and treatment methods for hepatitis C.